HARBOR
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
- Investigator
- Sub Subramony
- Status
- Accepting Candidates
- Ages
- 16 Years - 65 Years
- Sexes
- All
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with鈥�
- Investigator
- Thomas J George
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All
u-STOP LVAD Bleed
This is a Phase I, single ascending dose, first in human, open-label, non-controlled, dose-escalation trial that will investigate intravenous infusions of Umbilical cord lining stem cells (UCLSCs) in Left Ventricular Assist Device (LVAD)鈥�
- Investigator
- Mustafa M Ahmed
- Status
- Accepting Candidates
- Ages
- 18 Years - 80 Years
- Sexes
- All